<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13451">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02139007</url>
  </required_header>
  <id_info>
    <org_study_id>F120404006</org_study_id>
    <nct_id>NCT02139007</nct_id>
  </id_info>
  <brief_title>Effectiveness of DiscontinuinG bisphosphonatEs Study: R21 Pilot Study</brief_title>
  <acronym>EDGE</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study evaluating the recruitment strategies for sites and patients, data
      collection instruments, follow-up procedures, administrative processes, and the proposed
      management strategy for the future large scale national trial. This pilot study is 6 months
      in length.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Clinical site recruitment rate</measure>
    <time_frame>6 months following enrollment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Ability to recruit clinical trial sites for this pilot study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participant recruitment rate</measure>
    <time_frame>6 months following enrollment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Rate of participant recruitment into this pilot study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Contracting and procedures</measure>
    <time_frame>6 months following enrollment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time spent on contracting and initiating sites for this clinical study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Administrative procedures</measure>
    <time_frame>6 months following enrollment.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluation of all University of Alabama at Birmingham administrative procedures with this pilot study ie. time to complete contracting, time to complete Institutional Review Board/human subjects training verification for study sites.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Osteonecrosis of the jaw</measure>
    <time_frame>6 months following enrollment</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Via follow-up survey patients will self report diagnoses of osteonecrosis of the jaw.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atypical femoral fracture</measure>
    <time_frame>6 months following enrollment</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Patient reported fracture rate at 6 months after enrollment via survey.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical fracture rate</measure>
    <time_frame>6 months following enrollment</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Patient reported fracture rate at 6 months following enrollment via survey.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Continuation Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Alendronate continuation arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Discontinuation Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Alendronate discontinuation arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alendronate</intervention_name>
    <arm_group_label>Continuation Arm</arm_group_label>
    <arm_group_label>Discontinuation Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1.Females 65+

        2.3+ years of alendronate (Fosamax/Binosto) use

        3. Valid social security number

        Exclusion Criteria:

          1. History of any other metabolic bone condition, such as Paget Disease of Bone

          2. Currently receiving treatment for ongoing cancer, excluding non-melanoma skin cancer.

          3. Has significant underlying illness that would be expected to prevent completion of
             the study (e.g., life-threatening disease likely to limit survival to less than 3
             years)?

          4. HIV positive

          5. Involved in a conflicting (investigational drug) clinical trial
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeff Foster, MPH</last_name>
      <phone>205-996-6086</phone>
      <email>fosterau@uab.edu</email>
    </contact>
    <investigator>
      <last_name>Kenneth G Saag, MD, MsC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 23, 2014</lastchanged_date>
  <firstreceived_date>May 13, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alendronate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
